{"id":489227,"date":"2020-06-09T19:16:01","date_gmt":"2020-06-09T19:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=489227"},"modified":"2020-06-09T19:16:01","modified_gmt":"2020-06-09T19:16:01","slug":"prostate-cancer-epidemiological-analysis-prevalence-segmentation-and-forecast-trends-201730","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/prostate-cancer-epidemiological-analysis-prevalence-segmentation-and-forecast-trends-201730_489227.html","title":{"rendered":"Prostate Cancer Epidemiological Analysis: Prevalence, Segmentation, and Forecast Trends 2017-30"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1591708096.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Prostate Cancer Epidemiological Analysis: Prevalence, Segmentation, and Forecast Trends 2017-30\" src=\"https:\/\/www.abnewswire.com\/uploads\/1591708096.jpeg\" alt=\"Prostate Cancer Epidemiological Analysis: Prevalence, Segmentation, and Forecast Trends 2017-30\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Prostate Cancer Epidemiological Analysis<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">According to DelveInsight\u2019s Prostate Cancer Epidemiological analysis, by 2020, a total of 7,494,882 males will be diagnosed with it in the 7MM, and the US alone will account for 3,478,728 Prostate Cancer prevalent cases.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-epidemiology-forecast\">&#8216;Prostate cancer &#8211; Epidemiology Forecast to 2030&#8217;<\/a><\/strong> report delivers an in-depth understanding of the disease, historical and forecasted Prostate cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Geography Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The United States<\/li>\n<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/li>\n<li>Japan<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Study Period<\/strong>: 2017-2030<\/p>\n<p style=\"text-align: justify;\"><strong>Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Prostate Cancer is cancer that develops slowly and remains confined to prostate glands initially, invading other organs progressively.<\/p>\n<p style=\"text-align: justify;\">Prostate Cancer is the third most prevalent type of cancer in the US and the fourth most common form of cancer worldwide, Prostate Cancer is the most leading cause of death in men after lung cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-epidemiology-forecast\">https:\/\/www.delveinsight.com\/sample-request\/prostate-cancer-epidemiology-forecast<\/a> <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Prostate Cancer Epidemiology <\/strong><\/p>\n<p style=\"text-align: justify;\">The Prostate cancer epidemiology division provide insights about historical and current Prostate cancer patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;<\/p>\n<p style=\"text-align: justify;\">According to DelveInsight&rsquo;s Prostate Cancer Epidemiological analysis, by 2020, a total of 7,494,882 males will be diagnosed with it in the 7MM, and the US alone will account for 3,478,728 Prostate Cancer prevalent cases.<\/p>\n<p style=\"text-align: justify;\"><strong>Click to know more: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-market\/\">https:\/\/www.delveinsight.com\/blog\/prostate-cancer-market\/<\/a> <\/strong><\/p>\n<p style=\"text-align: justify;\">The disease epidemiology covered in the report provides historical as well as forecasted Prostate Cancer epidemiology segmented as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalent Cases of Prostate Cancer<\/li>\n<li>Total Diagnosed Cases of Prostate Cancer<\/li>\n<li>Age-specific Cases of Prostate Cancer<\/li>\n<li>Total Diagnosed cases of Prostate Cancer patients by Clinical Stages<\/li>\n<li>Total Non-metastatic and Metastatic Cases of CSPC\/HSPC and CRPC<\/li>\n<li>Total Treated cases of Non-metastatic CSPC\/HSPC and CRPC<\/li>\n<li>Total Treated Cases of metastatic HSPC\/CSPC, and CRPC<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Click to know more about report offerings: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-epidemiology-forecast\">https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-epidemiology-forecast<\/a> <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-epidemiology-forecast\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/d97533bd13150bfaadf3fc0a4d09315b.jpg\" alt=\"\" \/><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Prostate cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Prostate cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of Prostate cancer in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of Prostate cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Prostate cancer<\/li>\n<li>The report provides the segmentation of the Prostate cancer epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Key Insights&nbsp;<\/li>\n<li>Executive Summary of Prostate cancer<\/li>\n<li>Prostate cancer: Disease Background and Overview<\/li>\n<li>Patient Journey<\/li>\n<li>Epidemiology and Patient Population<\/li>\n<li>Epidemiology Scenario: 7MM<\/li>\n<\/ol>\n<ul style=\"text-align: justify;\">\n<li>United States Epidemiology<\/li>\n<li>EU-5 Country-wise Epidemiology<\/li>\n<li>Japan Epidemiology<\/li>\n<\/ul>\n<ol style=\"text-align: justify;\">\n<li>Treatment Algorithm, Current Treatment, and Medical Practices<\/li>\n<li>KOL Views<\/li>\n<li>Unmet Needs<\/li>\n<li>Appendix<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<li>About DelveInsight<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong><em>*The table of contents is not exhaustive; will be provided in the final report<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About <\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57049.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Vinita Rakheja <br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=prostate-cancer-epidemiological-analysis-prevalence-segmentation-and-forecast-trends-201730\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=prostate-cancer-epidemiological-analysis-prevalence-segmentation-and-forecast-trends-201730\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prostate Cancer Epidemiological Analysis According to DelveInsight\u2019s Prostate Cancer Epidemiological analysis, by 2020, a total of 7,494,882 males will be diagnosed with it in the 7MM, and the US alone will account for 3,478,728 Prostate Cancer prevalent cases. DelveInsight&#8217;s &#8216;Prostate &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/prostate-cancer-epidemiological-analysis-prevalence-segmentation-and-forecast-trends-201730_489227.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-489227","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/489227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=489227"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/489227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=489227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=489227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=489227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}